The history of vaccination against cytomegalovirus

Cytomegalovirus pp65 limits dissemination but is dispensable for persistence

(2014) Daniel Malouli et al.   JOURNAL OF CLINICAL INVESTIGATION

Universal neonatal cytomegalovirus screening using saliva – Report of clinical experience

(2014) Galia Barkai et al.   JOURNAL OF CLINICAL VIROLOGY

Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease

(2014) Tong-Ming Fu et al.   VACCINE

Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection

(2014) Tatiana M. Lanzieri et al.   VACCINE

Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice

(2014) Yingxia Wen et al.   VACCINE

Enveloped Virus-Like Particle Expression of Human Cytomegalovirus Glycoprotein B Antigen Induces Antibodies with Potent and Broad Neutralizing Activity

(2013) Marc Kirchmeier et al.   Clinical and Vaccine Immunology

Cytomegalovirus Vaccine Strain Towne-Derived Dense Bodies Induce Broad Cellular Immune Responses and Neutralizing Antibodies That Prevent Infection of Fibroblasts and Epithelial Cells

(2013) C. Cayatte et al.   JOURNAL OF VIROLOGY

Fetal Human Cytomegalovirus Transmission Correlates with Delayed Maternal Antibodies to gH/gL/pUL128-130-131 Complex during Primary Infection

(2013) Daniele Lilleri et al.   PLoS One

Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant

(2012) Corinna La Rosa et al.   JOURNAL OF INFECTIOUS DISEASES

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial

(2012) Mohamed A Kharfan-Dabaja et al.   LANCET INFECTIOUS DISEASES

Nonviral delivery of self-amplifying RNA vaccines

(2012) A. J. Geall et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The next generation recombinant human cytomegalovirus vaccine candidates—Beyond gB

(2012) Anders E. Lilja et al.   VACCINE

Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus

(2012) Tong-Ming Fu et al.   VACCINE

Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies

(2012) Rebecca J. Loomis et al.   VACCINE

Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice

(2012) Devon J. Shedlock et al.   Human Vaccines & Immunotherapeutics

Serum antibody response to the gH/gL/pUL128–131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections

(2011) Emilia Genini et al.   JOURNAL OF CLINICAL VIROLOGY

Glycoprotein B Vaccine Is Capable of Boosting Both Antibody and CD4 T-Cell Responses to Cytomegalovirus in Chronically Infected Women

(2011) Steffanie Sabbaj et al.   JOURNAL OF INFECTIOUS DISEASES

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

(2011) Paul D Griffiths et al.   LANCET

Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection

(2011) Dai Wang et al.   VACCINE

Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients

(2010) Per Ljungman et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant

(2010) Sabine Becke et al.   VACCINE

Isolation of Human Monoclonal Antibodies That Potently Neutralize Human Cytomegalovirus Infection by Targeting Different Epitopes on the gH/gL/UL128-131A Complex

(2009) A. Macagno et al.   JOURNAL OF VIROLOGY

Vaccine Prevention of Maternal Cytomegalovirus Infection

(2009) Robert F. Pass et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers

(2009) David I. Bernstein et al.   VACCINE

Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult Subjects

(2008) Mary K. Wloch et al.   JOURNAL OF INFECTIOUS DISEASES